Combinatorial therapy with BAR502 and UDCA resets FXR and GPBAR1 signaling and reverses liver histopathology in a dietetic model of non-alcoholic fatty liver disease

Published: 13 September 2022| Version 1 | DOI: 10.17632/bs4hshm249.1
Contributors:
silvia marchianò,
Michele Biagioli,
Stefano Fiorucci

Description

Non-alcoholic steatosis (NAFLD) and steatohepatitis (NASH) are two highly prevalent human disorders for which therapy remains suboptimal. In the present study we have compared the effects of BAR502, a dual FXR/GPBAR1 ligand) alone or in combination with ursodeoxycholic acid (UDCA) in a model of NAFLD/NASH induced by feeding mice with a Western diet for 10 weeks.

Files

Institutions

Universita degli Studi di Perugia Dipartimento di Medicina

Categories

Bile Acid, Transcriptome, Non-Alcoholic Fatty Liver Disease

License